Brought to you by Eli LillyFeeling stagnant at work? Hungry for change? Craving something new? Your new career could ...

Lilly Limerick is set to be the global pharmaceutical leader's most technically advanced manufacturing site to date ...

Eli Lilly will invest over €1.6bn to expand its manufacturing footprint in Ireland as it ramps up production capacity across ...

The project is currently awaiting planning approval, with a formal application to be submitted to the Limerick City and County Council. Simultaneously, Eli Lilly is investing $800 million to ...

Eli Lilly has added $1 billion to its investment ... The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has opted to double ...

Eli Lilly has said it is seeking permission to ... The pharma group has said the total investment in the proposed facility in Limerick would be more than €400 million ($445 million), and could ...

EBGLYSS works Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...